Lam Phuong Nguyen, DO
Surgical Critical Care · Puyallup, WANPI 1841516879
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for surgical critical care clinicians in WA, where the typical reported total is $764.
Across 31 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sentec, Inc.$151
- Boehringer Ingelheim$96
- GSK$84
- Sanofi$66
- Mylan Specialty L.p.$61
- Philips North America LLC$51
- plus $254 from 9 others
What the payments were for
- Food & beverage$75198%
- Education$132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sentec, Inc. | 1 | $151 |
| Boehringer Ingelheim | 3 | $96 |
| GSK | 5 | $84 |
| Sanofi | 3 | $66 |
| Mylan Specialty L.p. | 3 | $61 |
| Philips North America LLC | 3 | $51 |
| Merck | 3 | $51 |
| Straumann USA LLC | 1 | $37 |
| AstraZeneca | 2 | $32 |
| United Therapeutics Corporation | 2 | $29 |
| Amgen | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Circassia Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$764 in reported general payments places this provider in the 50th percentile of 22 surgical critical care providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 226 | $178,715 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $28,874 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $21,587 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $15,140 |
| Spiriva RespimatTiotropium Bromide | 11 | $13,826 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $10,331 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,901 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $5,353 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,741 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $3,345 |
| Montelukast Sodium | 24 | $311 |
| Fluticasone Propionate | 14 | $208 |
| Omeprazole | 13 | $151 |
| Prednisone | 23 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $84 | $204,186267 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $96 | $42,70054 claims |
| AstraZenecaSymbicort | $32 | $6,90123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 22 surgical critical care providers in Washington.
Other surgical critical care in Puyallup
- Saman ArbabiSeattle$14K
- Christopher HultsMukilteo$8K
- Tim LeeVancouver$8K
- Long TranTacoma$6K
- Gweniviere CapronRenton$3K
- Seth WelbornRichland$2K
- Michael ParmleyRichland$1K
- Kanika ChawlaRichland$1K
- Anooradha RamanEverett$1K
- Edgar FigueredoSeattle$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.